End of treatment ‐ homozygous major · people who smoke
It is very uncertain whether active NRT changes end of treatment ‐ homozygous major compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (very low certainty).
1 finding from 1 review
End of treatment ‐ heterozygous · people who smoke
It is very uncertain whether active NRT changes end of treatment ‐ heterozygous compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (very low certainty).
1 finding from 1 review
End of treatment ‐ homozygous minor · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
End of treatment · people who smoke
Active NRT probably leads to higher end of treatment compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
End of treatment ‐ slow NMR · people who smoke
Active NRT probably leads to higher end of treatment ‐ slow NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
End of treatment ‐ normal NMR · people who smoke
Active NRT showed no clear difference in end of treatment ‐ normal NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (low certainty).
1 finding from 1 review
Abstinence at end of treatment ‐ homozygous minor · people who smoke
Active NRT may leads to higher abstinence at end of treatment ‐ homozygous minor compared with placebo ‐ rs1051730 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
End of treatment · people who smoke
Active NRT showed no clear difference in end of treatment compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (moderate certainty).
1 finding from 1 review
End of treatment ‐ homozygous major · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous major compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
End of treatment ‐ heterozygous · people who smoke
Active NRT leads to higher end of treatment ‐ heterozygous compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (high certainty).
1 finding from 1 review
End of treatment ‐ homozygous minor · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
Active range of motion of the ankle joint · children with ITW gait
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with inflammatory bowel disease
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
Length of hospital stay · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Cost of oral care · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Amount of analgesia · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Incidence of systemic infection · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found